TLR9 and lymphoma: For example, the anti-lymphoma effect of PG545 in vivo seems to require NK (natural killer) cell activation and this activation involves PG545 acting via TLR9 (toll-like receptor-9) to trigger dendritic cells to release IL-12, which is necessary for PG545 activation of NK cells [77].